Tag: Diabetes: Drugs
Glipizide Linked to Highest MACE-4 Risk in Individuals With Type 2 Diabetes
Highest risk seen with glipizide versus other sulfonylureas and DPP4 inhibitors as second-line therapy
GLP-1 Receptor Agonist Use in T2D Tied to Increased Risk for GERD, GERD Complications
Risk ratios were 1.27 and 1.55 for GERD and its complications during a median follow-up of three years for GLP-1 RA versus SGLT-2 inhibitor users
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
Combined use of SGLT2 inhibitors and GLP-1 receptor agonists also significantly increased the risk for falls
Common Medications Tied to Older Age at Onset of Parkinson Disease
Almost 10-year delay seen for patients who were started on adrenergic blockers before onset of PD symptoms
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
Authors say large, multisite study should provide reassurance for short-term risk
Once-Weekly Efsitora Noninferior to Degludec for Type 2 Diabetes
Once-weekly efsitora noninferior to once-daily degludec for decrease in mean glycated hemoglobin level
Risk for Dementia Similar With SGLT2 Inhibitors, Dulaglutide in T2DM
Estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 versus dulaglutide among older adults
Long-Term Sulfonylurea Use Tied to Impaired Awareness of Hypoglycemia
Odds are lessened with regular diabetes-related medical care
ACP: Recommendations Developed for Newer Type 2 Diabetes Medications
Strong recommendation given for addition of SGLT-2 or GLP-1 agonist to metformin and lifestyle modifications
